Adicet Bio, Inc. (ACET)Healthcare | Biotechnology | Boston, United States | NasdaqCM
8.22 USD
+0.17
(2.112%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 8.35 +0.13 (1.583%) ⇧ (April 17, 2026, 7 p.m. EDT) Short-term: ★★☆☆☆ | Long-term: ★★★★☆ | Dividends: ★☆☆☆☆ |
Hot Take | April 19, 2026, 1:03 a.m. EDT
The bearish forecasting model (-10%) and heavy short-term put activity (via OI concentration at low strikes) have triggered a defensive stance in the options market, likely a response to the technical breach of the 6.00 support level (implied by current price action and 52-week lows). However, the fundamental data reveals a massive value trap scenario priced in: a company trading at 0.55x Book Value (Price 8.22 vs Book 14.82) with an incredible 1.0 recommendation and analyst targets implying a >200-300% upside, currently suppressed only by near-term cash burn fears. This divergence suggests the market is over-penalizing short-term revenue shortfalls on a balance sheet that is nearly debt-free and undervalued, making this an accumulation zone for longer-term investors waiting for the talent flow (RA Capital) to ignite a re-rating. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.108540 |
| AutoARIMA | 0.179163 |
| AutoETS | 0.181027 |
| MSTL | 0.181247 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 81% |
| H-stat | 0.69 |
| Ljung-Box p | 0.026 |
| Jarque-Bera p | 0.036 |
| Excess Kurtosis | 1.57 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 9.257 |
| Market Cap | 78,912,000 |
| Forward P/E | -2.45 |
| Beta | 1.58 |
| Website | https://www.adicetbio.com |
As of April 19, 2026, 1:03 a.m. EDT: Speculators are heavily positioning for downside protection and long-dated low-strike moves while avoiding OTM upside bets. On the 1M expiration, massive OI exists at 7.5 strikes (both calls approx 8% OTM and puts at ATM) paired with significant out-of-the-money OI on deep strikes (0.5/1.0 for calls, 5.0 for puts), suggesting a non-directional defense or a massive gamma squeeze target. The extreme imbalance in short-term premiums (calls at $1.0 strike have 0.0 IV vs 3.47 at ATM for calls, indicating a structural pricing anomaly or lack of supply in deep ITM calls compared to Puts) and the presence of substantial Put OI on 04-17 suggests near-term uncertainty. The pricing on the 10M long strikes lacks a pervasive skews of specific direction except for a high OI of deep OTM puts, hinting at a 'short-term pain, long-term gain' outlook where movement is expected to be wide but not strictly bullish in the immediate term.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.09551054 |
| Address1 | 131 Dartmouth Street |
| Address2 | 3rd Floor |
| All Time High | 2,362.864 |
| All Time Low | 6.01 |
| Ask | 10.43 |
| Ask Size | 2 |
| Audit Risk | 9 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 208,820 |
| Average Daily Volume3 Month | 155,873 |
| Average Volume | 155,873 |
| Average Volume10Days | 208,820 |
| Beta | 1.578 |
| Bid | 5.92 |
| Bid Size | 2 |
| Board Risk | 10 |
| Book Value | 14.825 |
| City | Boston |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 8.22 |
| Current Ratio | 7.474 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 8.47 |
| Day Low | 8.15 |
| Debt To Equity | 9.257 |
| Display Name | Adicet Bio |
| Dividend Date | 1,600,214,400 |
| Earnings Timestamp | 1,773,345,600 |
| Earnings Timestamp End | 1,778,097,600 |
| Earnings Timestamp Start | 1,778,097,600 |
| Ebitda | -115,733,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.479 |
| Enterprise Value | -55,433,248 |
| Eps Current Year | -9.744 |
| Eps Forward | -3.355 |
| Eps Trailing Twelve Months | -16.95 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 7.064 |
| Fifty Day Average Change | 1.1560001 |
| Fifty Day Average Change Percent | 0.16364667 |
| Fifty Two Week Change Percent | -9.551054 |
| Fifty Two Week High | 17.44 |
| Fifty Two Week High Change | -9.22 |
| Fifty Two Week High Change Percent | -0.5286697 |
| Fifty Two Week Low | 6.01 |
| Fifty Two Week Low Change | 2.21 |
| Fifty Two Week Low Change Percent | 0.36772045 |
| Fifty Two Week Range | 6.01 - 17.44 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,516,977,000,000 |
| Float Shares | 6,799,002 |
| Forward Eps | -3.355 |
| Forward P E | -2.4500747 |
| Free Cashflow | -53,868,752 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 102 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00896 |
| Held Percent Institutions | 0.72523004 |
| Implied Shares Outstanding | 9,600,000 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,767,052,800 |
| Last Split Factor | 1:16 |
| Long Business Summary | Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts. |
| Long Name | Adicet Bio, Inc. |
| Market | us_market |
| Market Cap | 78,912,000 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_310073311 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -116,803,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 78,940,043 |
| Number Of Analyst Opinions | 6 |
| Open | 8.3 |
| Operating Cashflow | -95,246,000 |
| Operating Margins | 0.0 |
| Overall Risk | 10 |
| Payout Ratio | 0.0 |
| Phone | 650 503 9095 |
| Post Market Change | 0.1300993 |
| Post Market Change Percent | 1.5827165 |
| Post Market Price | 8.3501 |
| Post Market Time | 1,776,466,813 |
| Previous Close | 8.05 |
| Price Eps Current Year | -0.84359604 |
| Price Hint | 2 |
| Price To Book | 0.5544688 |
| Profit Margins | 0.0 |
| Quick Ratio | 7.379 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | 0.17 |
| Regular Market Change Percent | 2.1118 |
| Regular Market Day High | 8.47 |
| Regular Market Day Low | 8.15 |
| Regular Market Day Range | 8.15 - 8.47 |
| Regular Market Open | 8.3 |
| Regular Market Previous Close | 8.05 |
| Regular Market Price | 8.22 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 185,587 |
| Return On Assets | -0.36998 |
| Return On Equity | -0.67552 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 6 |
| Shares Outstanding | 9,596,407 |
| Shares Percent Shares Out | 0.0684 |
| Shares Short | 656,546 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 640,053 |
| Short Name | Adicet Bio, Inc. |
| Short Percent Of Float | 0.08140001 |
| Short Ratio | 5.93 |
| Source Interval | 15 |
| State | MA |
| Symbol | ACET |
| Target High Price | 128.0 |
| Target Low Price | 18.0 |
| Target Mean Price | 53.0 |
| Target Median Price | 26.0 |
| Total Cash | 158,530,000 |
| Total Cash Per Share | 14.748 |
| Total Debt | 14,738,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -16.95 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 9.96661 |
| Two Hundred Day Average Change | -1.7466097 |
| Two Hundred Day Average Change Percent | -0.17524612 |
| Type Disp | Equity |
| Volume | 185,587 |
| Website | https://www.adicetbio.com |
| Zip | 2,116 |